Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug
Vanda Pharmaceuticals shares rose 28.1% to $9.01 after the FDA approved Nereus to prevent motion-induced vomiting. Late-stage trials showed vomiting rates of 10%–20% on Nereus versus 38%–44% on placebo. Vanda plans to launch the drug in the coming months, with investors watching pricing and rollout against established over-the-counter competitors.